Novo Nordisk, the well-known pharmaceutical company, has announced significant changes to its diabetes drugs, Ozempic and Victoza.
Novo Nordisk will ration Ozempic starter kits in Europe due to increased demand for the drug as an off-label treatment for weight loss. The company has also made the difficult decision to temporarily reduce the supply of Victoza, another diabetes drug, in order to prioritize the production of Ozempic.
The intermittent shortage of Ozempic is expected to persist throughout 2024, while the shortage of Victoza is expected to last until at least the second quarter of next year.
Novo Nordisk has urged healthcare professionals not to start any new patients on Victoza until supplies are stabilized. This is a serious matter, as patients who rely on Victoza for their diabetes management may face problems accessing the medicines they need.
For Ozempic, Novo Nordisk will limit the supply of the starting dose of 0.25 milligrams to prioritize existing patients already on weekly therapy.
In an effort to curb the export of Ozempic, Germany’s drug regulator is considering imposing a ban. Several other EU member states, including France and Austria, have already taken similar measures to ensure the availability of Ozempic for diabetic patients.
Despite these measures, the clamor for Ozempic in Europe shows no signs of abating. Even with the launch of Wegovy, Novo Nordisk’s weight loss drug, demand for Ozempic continues to outstrip its availability. Production bottlenecks have further exacerbated the situation, leaving the industry struggling to meet global demand for weight loss drugs.
the mail Novo Nordisk is rationing diabetes drugs Ozempic and Victoza due to growing demand appeared first NewsGPT.ai.
English 
Español de Venezuela 